메뉴 건너뛰기




Volumn 166, Issue 5, 2013, Pages 831-838

Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: Rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in Uncertain des Candidates study

(21)  Valgimigli, Marco a,b   Patialiakas, Athanasios a   Thury, Attila c   Colangelo, Salvatore d   Campo, Gianluca a   Tebaldi, Matteo a   Ungi, Imre c   Tondi, Stefano e   Roffi, Marco f   Menozzi, Alberto g   De Cesare, Nicoletta h   Garbo, Roberto d   Meliga, Emanuele i   Testa, Luca j   Gabriel, Henrique M k   Airoldi, Flavio l   Ferlini, Marco m   Liistro, Francesco n   Dellavalle, Antonio o   Vranckx, Pascal p   more..


Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOY; CLOPIDOGREL; COBALT; EVEROLIMUS; PACLITAXEL; PHOSPHORYLCHOLINE; RAPAMYCIN; ZOTAROLIMUS;

EID: 84886953167     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.07.033     Document Type: Article
Times cited : (18)

References (23)
  • 1
    • 42249090036 scopus 로고    scopus 로고
    • Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: The MULTISTRATEGY randomized trial
    • M. Valgimigli, G. Campo, and G. Percoco Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial JAMA 299 15 2008 1788 1799
    • (2008) JAMA , vol.299 , Issue.15 , pp. 1788-1799
    • Valgimigli, M.1    Campo, G.2    Percoco, G.3
  • 2
    • 33847766568 scopus 로고    scopus 로고
    • Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents
    • A. Kastrati, J. Mehilli, and J. Pache Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents N Engl J Med 356 10 2007 1030 1039
    • (2007) N Engl J Med , vol.356 , Issue.10 , pp. 1030-1039
    • Kastrati, A.1    Mehilli, J.2    Pache, J.3
  • 3
    • 34948904387 scopus 로고    scopus 로고
    • Effectiveness and safety of drug-eluting stents in Ontario
    • J.V. Tu, J. Bowen, and M. Chiu Effectiveness and safety of drug-eluting stents in Ontario N Engl J Med 357 14 2007 1393 1402
    • (2007) N Engl J Med , vol.357 , Issue.14 , pp. 1393-1402
    • Tu, J.V.1    Bowen, J.2    Chiu, M.3
  • 4
    • 84876141722 scopus 로고    scopus 로고
    • Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY)
    • M. Valgimigli, G. Campo, and S. Gambetti Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY) Int J Cardiol 165 1 2013 134 141
    • (2013) Int J Cardiol , vol.165 , Issue.1 , pp. 134-141
    • Valgimigli, M.1    Campo, G.2    Gambetti, S.3
  • 6
    • 78651430525 scopus 로고    scopus 로고
    • Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents
    • L. Mauri, J.M. Massaro, and S. Jiang Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents JACC Cardiovasc Interv 3 12 2010 1240 1249
    • (2010) JACC Cardiovasc Interv , vol.3 , Issue.12 , pp. 1240-1249
    • Mauri, L.1    Massaro, J.M.2    Jiang, S.3
  • 7
    • 84867746832 scopus 로고    scopus 로고
    • Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: A randomised, multicentre, open-label, controlled trial
    • Camenzind E, Wijns W, Mauri L, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet;380(9851):1396-405.
    • Lancet , vol.380 , Issue.9851 , pp. 1396-1405
    • Camenzind, E.1    Wijns, W.2    Mauri, L.3
  • 8
    • 79952278254 scopus 로고    scopus 로고
    • Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: Five year outcomes in the ENDEAVOR II study
    • J. Fajadet, W. Wijns, and G.J. Laarman Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 6 5 2010 562 567
    • (2010) EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology , vol.6 , Issue.5 , pp. 562-567
    • Fajadet, J.1    Wijns, W.2    Laarman, G.J.3
  • 9
    • 79956278957 scopus 로고    scopus 로고
    • Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in de Novo Native Coronary Artery Lesions)
    • D.E. Kandzari, L. Mauri, and J.J. Popma Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 4 5 2011 543 550
    • (2011) JACC Cardiovasc Interv , vol.4 , Issue.5 , pp. 543-550
    • Kandzari, D.E.1    Mauri, L.2    Popma, J.J.3
  • 10
    • 84876413538 scopus 로고    scopus 로고
    • The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent
    • A.J. Kirtane, M.B. Leon, and M.W. Ball The "Final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent JACC Cardiovasc Interv 6 4 2013 325 333
    • (2013) JACC Cardiovasc Interv , vol.6 , Issue.4 , pp. 325-333
    • Kirtane, A.J.1    Leon, M.B.2    Ball, M.W.3
  • 11
    • 79959497515 scopus 로고    scopus 로고
    • Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial
    • T. Pilgrim, L. Raber, and A. Limacher Comparison of titanium-nitride- oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial JACC Cardiovasc Interv 4 6 2011 672 682
    • (2011) JACC Cardiovasc Interv , vol.4 , Issue.6 , pp. 672-682
    • Pilgrim, T.1    Raber, L.2    Limacher, A.3
  • 12
    • 84867746832 scopus 로고    scopus 로고
    • Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: A randomised, multicentre, open-label, controlled trial
    • E. Camenzind, W. Wijns, and L. Mauri Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial Lancet 380 9851 2012 1396 1405
    • (2012) Lancet , vol.380 , Issue.9851 , pp. 1396-1405
    • Camenzind, E.1    Wijns, W.2    Mauri, L.3
  • 13
    • 84865309452 scopus 로고    scopus 로고
    • 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents
    • M. Maeng, H.H. Tilsted, and L.O. Jensen 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents JACC Cardiovasc Interv 5 8 2012 812 818
    • (2012) JACC Cardiovasc Interv , vol.5 , Issue.8 , pp. 812-818
    • Maeng, M.1    Tilsted, H.H.2    Jensen, L.O.3
  • 14
    • 77957558782 scopus 로고    scopus 로고
    • Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: The ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial
    • D.W. Park, Y.H. Kim, and S.C. Yun Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial J Am Coll Cardiol 56 15 2010 1187 1195
    • (2010) J Am Coll Cardiol , vol.56 , Issue.15 , pp. 1187-1195
    • Park, D.W.1    Kim, Y.H.2    Yun, S.C.3
  • 15
    • 72049099355 scopus 로고    scopus 로고
    • Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction
    • C.W. Lee, D.W. Park, and S.H. Lee Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction Am J Cardiol 104 10 2009 1370 1376
    • (2009) Am J Cardiol , vol.104 , Issue.10 , pp. 1370-1376
    • Lee, C.W.1    Park, D.W.2    Lee, S.H.3
  • 16
    • 77952744608 scopus 로고    scopus 로고
    • 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents
    • R.A. Byrne, A. Kastrati, and K. Tiroch 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents J Am Coll Cardiol 55 23 2010 2536 2543
    • (2010) J Am Coll Cardiol , vol.55 , Issue.23 , pp. 2536-2543
    • Byrne, R.A.1    Kastrati, A.2    Tiroch, K.3
  • 17
    • 84867050148 scopus 로고    scopus 로고
    • A new strategy for discontinuation of dual antiplatelet therapy: The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)
    • B.K. Kim, M.K. Hong, and D.H. Shin A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) J Am Coll Cardiol 60 15 2012 1340 1348
    • (2012) J Am Coll Cardiol , vol.60 , Issue.15 , pp. 1340-1348
    • Kim, B.K.1    Hong, M.K.2    Shin, D.H.3
  • 18
    • 84855395899 scopus 로고    scopus 로고
    • Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: Results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial
    • W.C. Kang, T. Ahn, and K. Lee Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 7 8 2011 936 943
    • (2011) EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology , vol.7 , Issue.8 , pp. 936-943
    • Kang, W.C.1    Ahn, T.2    Lee, K.3
  • 19
    • 84860135329 scopus 로고    scopus 로고
    • Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial
    • M. Valgimigli, G. Campo, and M. Monti Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 16 2012 2015 2026
    • (2012) Circulation , vol.125 , Issue.16 , pp. 2015-2026
    • Valgimigli, M.1    Campo, G.2    Monti, M.3
  • 20
    • 80054972182 scopus 로고    scopus 로고
    • Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents
    • D.E. Kandzari, C.S. Barker, and M.B. Leon Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents JACC Cardiovasc Interv 4 10 2011 1119 1128
    • (2011) JACC Cardiovasc Interv , vol.4 , Issue.10 , pp. 1119-1128
    • Kandzari, D.E.1    Barker, C.S.2    Leon, M.B.3
  • 21
    • 72149133094 scopus 로고    scopus 로고
    • Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: The ENDEAVOR OCT trial
    • J.S. Kim, I.K. Jang, and C. Fan Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial JACC Cardiovasc Interv 2 12 2009 1240 1247
    • (2009) JACC Cardiovasc Interv , vol.2 , Issue.12 , pp. 1240-1247
    • Kim, J.S.1    Jang, I.K.2    Fan, C.3
  • 22
    • 84886954187 scopus 로고    scopus 로고
    • Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)
    • [Epub ahead of print]
    • Valgimigli M, Borghesi M, Tebaldi M, et al. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J; [Epub ahead of print].
    • Eur Heart J
    • Valgimigli, M.1    Borghesi, M.2    Tebaldi, M.3
  • 23
    • 84875596758 scopus 로고    scopus 로고
    • Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)
    • M. Valgimigli, M. Borghesi, and M. Tebaldi Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) Eur Heart J 34 12 2013 909 919
    • (2013) Eur Heart J , vol.34 , Issue.12 , pp. 909-919
    • Valgimigli, M.1    Borghesi, M.2    Tebaldi, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.